Skip to main content

Advertisement

SpringerLink
Log in

T Cell-Depleted and T Cell-Replete HLA-Haploidentical Stem Cell Transplantation for Non-malignant Disorders

  • Stem Cell Transplantation (R Maziarz, Section Editor)
  • Published:
Current Hematologic Malignancy Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

Hematopoietic stem cell transplantation (HSCT) is a treatment option for children with malignant and non-malignant disorders as well as an expanding number of inherited disorders. However, only a limited portion of patients in the need of an allograft have an HLA-compatible, either related or unrelated, donor. Haploidentical HSCT is now considered a valid treatment option, especially in view of the recent insights in terms of graft manipulation. This review will offer an overview of clinical results obtained through the use of haploidentical HSCT in non-malignant diseases. We will analyze major advantages and drawbacks of both T cell depleted and unmanipulated HSCT, discussing future challenges for further improving patients’ outcome.

Recent Findings

T cell depletion (TCD) aims to reduce the morbidity and mortality associated with graft-versus-host disease (GvHD). However, the delayed immune recovery and the risk of graft failure still remain potential problems. In the last years, the use of post-transplant cyclophosphamide has been shown to be an alternative effective strategy to prevent GvHD in recipients of haploidentical HSCT.

Summary

Recent data suggest that both T cell depleted and T cell-replete haplo-HSCT are suitable options to treat children with several types of non-malignant disorders lacking an HLA-identical donor.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Booth C, Lawson S, Veys P. The current role of T cell depletion in paediatric stem cell transplantation. Br J Haematol. 2013;162(2):177–90.

    Article  CAS  PubMed  Google Scholar 

  2. Tolar J, Sodani P, Symons H. Alternative donor transplant of benign primary hematologic disorders. Bone Marrow Transplant. 2015;50(5):619–27.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Rocha V, Locatelli F. Searching for alternative hematopoietic stem cell donors for pediatric patients. Bone Marrow Transplant. 2008;41(2):207–14.

    Article  CAS  PubMed  Google Scholar 

  4. Martelli MF, Aversa F, Bachar-Lustig E, Velardi A, Reich-Zelicher S, Tabilio A, et al. Transplants across human leukocyte antigen barriers. Semin Hematol. 2002;39(1):48–56.

    Article  PubMed  Google Scholar 

  5. Locatelli F, Bauquet A, Palumbo G, Moretta F, Bertaina A. Negative depletion of alpha/beta + T cells and of CD19+ B lymphocytes: a novel frontier to optimize the effect of innate immunity in HLA-mismatched hematopoietic stem cell transplantation. Immunol Lett. 2013;155(1-2):21–3.

    Article  CAS  PubMed  Google Scholar 

  6. Powles RL, Morgenstern GR, Kay HE, McElwain TJ, Clink HM, Dady PJ, et al. Mismatched family donors for bone-marrow transplantation as treatment for acute leukaemia. Lancet. 1983;1(8325):612–5.

    Article  CAS  PubMed  Google Scholar 

  7. Beatty PG, Clift RA, Mickelson EM, Nisperos BB, Flournoy N, Martin PJ, et al. Marrow transplantation from related donors other than HLA-identical siblings. N Engl J Med. 1985;313(13):765–71.

    Article  CAS  PubMed  Google Scholar 

  8. Szydlo R, Goldman JM, Klein JP, Gale RP, Ash RC, Bach FH, et al. Results of allogeneic bone marrow transplants for leukemia using donors other than HLA-identical siblings. J Clin Oncol. 1997;15(5):1767–77.

    Article  CAS  PubMed  Google Scholar 

  9. Pulsipher MA. Haplo is the new black. Blood. 2014;124(5):675–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Or-Geva N, Reisner Y. The evolution of T-cell depletion in haploidentical stem-cell transplantation. Br J Haematol. 2016;172(5):667–84.

    Article  PubMed  Google Scholar 

  11. Klein OR, Chen AR, Gamper C, Loeb D, Zambidis E, Llosa N, et al. Alternative-donor hematopoietic stem cell transplantation with post-transplantation cyclophosphamide for nonmalignant disorders. Biol Blood Marrow Transplant. 2016;22(5):895–901.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Reisner Y, Kapoor N, Kirkpatrick D, Pollack MS, Cunningham-Rundles S, Dupont B, et al. Transplantation for severe combined immunodeficiency with HLA-A, B, D, DR incompatible parental marrow cells fractionated by soybean agglutinin and sheep red blood cells. Blood. 1983;61(2):341–8.

    CAS  PubMed  Google Scholar 

  13. Railey MD, Lokhnygina Y, Buckley RH. Long-term clinical outcome of patients with severe combined immunodeficiency who received related donor bone marrow transplants without pretransplant chemotherapy or post-transplant GVHD prophylaxis. J Pediatr. 2009;155(6):834–40.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Fischer A, Durandy A, de Villartay JP, Vilmer E, Le Deist F, Gerota I, et al. HLA-haploidentical bone marrow transplantation for severe combined immunodeficiency using E rosette fractionation and cyclosporine. Blood. 1986;67(2):444–9.

    CAS  PubMed  Google Scholar 

  15. Gennery AR, Dickinson AM, Brigham K, Barge D, Spickett GP, Curtis A, et al. CAMPATH-1M T-cell depleted BMT for SCID: long-term follow-up of 19 children treated 1987–98 in a single center. Cytotherapy. 2001;3(3):221–32.

    Article  CAS  PubMed  Google Scholar 

  16. Mazzolari E, Forino C, Guerci S, Imberti L, Lanfranchi A, Porta F, et al. Long-term immune reconstitution and clinical outcome after stem cell transplantation for severe T-cell immunodeficiency. J Allergy Clin Immunol. 2007;120(4):892–9.

    Article  CAS  PubMed  Google Scholar 

  17. Antoine C, Muller S, Cant A, Cavazzana-Calvo M, Veys P, Vossen J, et al. Long-term survival and transplantation of haemopoietic stem cells for immunodeficiencies: report of the European experience 1968–99. Lancet. 2003;361(9357):553–60.

    Article  PubMed  Google Scholar 

  18. Aversa F, Tabilio A, Velardi A, Cunningham I, Terenzi A, Falzetti F, et al. Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. N Engl J Med. 1998;339(17):1186–93.

    Article  CAS  PubMed  Google Scholar 

  19. Gennery AR, Slatter MA, Grandin L, Taupin P, Cant AJ, Veys P, et al. Transplantation of hematopoietic stem cells and long-term survival for primary immunodeficiencies in Europe: entering a new century, do we do better? J Allergy Clin Immunol. 2010;126(3):602-10 e1–11.

    Article  Google Scholar 

  20. •• Pai SY, Logan BR, Griffith LM, Buckley RH, Parrott RE, Dvorak CC, et al. Transplantation outcomes for severe combined immunodeficiency, 2000-2009. N Engl J Med. 2014;371(5):434–46. The Primary Immune Deficiency Treatment Consortium (PIDTC) was formed to analyze the results of hematopoietic-cell transplantation in children with severe combined immunodeficiency (SCID) and other primary immunodeficiencies. They analyzed a huge cohort of HSCT demonstrating that transplants from donors other than matched siblings were associated with excellent survival among infants with SCID identified before the onset of infection.

  21. Fernandes JF, Rocha V, Labopin M, Neven B, Moshous D, Gennery AR, et al. Transplantation in patients with SCID: mismatched related stem cells or unrelated cord blood? Blood. 2012;119(12):2949–55.

    Article  CAS  PubMed  Google Scholar 

  22. • Zecca M, Strocchio L, Pagliara D, Comoli P, Bertaina A, Giorgiani G, et al. HLA-haploidentical T cell-depleted allogeneic hematopoietic stem cell transplantation in children with Fanconi anemia. Biol Blood Marrow Transplant. 2014;20(4):571–6. The first report on the outcome of 12 consecutive pediatric patients with Fanconi anemia (FA) who had neither an HLA-identical sibling nor an HLA-matched unrelated donor and who were given T cell-depleted, CD34(+) positively selected cells from a haploidentical related donor after a reduced-intensity, fludarabine-based conditioning regimen. This is the largest series of hematopoietic stem cell transplantation from a haploidentical related donor in FA patients reported to date.

  23. Klingebiel T, Cornish J, Labopin M, Locatelli F, Darbyshire P, Handgretinger R, et al. Results and factors influencing outcome after fully haploidentical hematopoietic stem cell transplantation in children with very high-risk acute lymphoblastic leukemia: impact of center size: an analysis on behalf of the Acute Leukemia and Pediatric Disease Working Parties of the European Blood and Marrow Transplant group. Blood. 2010;115(17):3437–46.

    Article  CAS  PubMed  Google Scholar 

  24. Aversa F, Terenzi A, Tabilio A, Falzetti F, Carotti A, Ballanti S, et al. Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse. J Clin Oncol. 2005;23(15):3447–54.

    Article  PubMed  Google Scholar 

  25. Guinan EC, Boussiotis VA, Neuberg D, Brennan LL, Hirano N, Nadler LM, et al. Transplantation of anergic histoincompatible bone marrow allografts. N Engl J Med. 1999;340(22):1704–14.

    Article  CAS  PubMed  Google Scholar 

  26. Di Ianni M, Falzetti F, Carotti A, Terenzi A, Castellino F, Bonifacio E, et al. Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation. Blood. 2011;117(14):3921–8.

    Article  PubMed  Google Scholar 

  27. Bader P, Soerensen J, Jarisch A, Ponstingl E, Krenn T, Faber J, et al. Rapid immune recovery and low TRM in haploidentical stem cell transplantation in children and adolescence using CD3/CD19-depleted stem cells. Best Pract Res Clin Haematol. 2011;24(3):331–7.

    Article  CAS  PubMed  Google Scholar 

  28. Locatelli F, Pende D, Mingari MC, Bertaina A, Falco M, Moretta A, et al. Cellular and molecular basis of haploidentical hematopoietic stem cell transplantation in the successful treatment of high-risk leukemias: role of alloreactive NK cells. Front Immunol. 2013;4:15.

    Article  PubMed  PubMed Central  Google Scholar 

  29. •• Bertaina A, Merli P, Rutella S, Pagliara D, Bernardo ME, Masetti R, et al. HLA-haploidentical stem cell transplantation after removal of alphabeta + T and B cells in children with nonmalignant disorders. Blood. 2014;124(5):822–6. Pylot study of haploidentical HSCT after depletion of TCRαβ + T lymphocytes and CD19+ B cells in children with nonmalignant disorders.

  30. Balashov D, Shcherbina A, Maschan M, Trakhtman P, Skvortsova Y, Shelikhova L, et al. Single-center experience of unrelated and haploidentical stem cell transplantation with tcralphabeta and CD19 depletion in children with primary immunodeficiency syndromes. Biol Blood Marrow Transplant. 2015;21(11):1955–62.

    Article  PubMed  Google Scholar 

  31. •• Merli P, Bertaina A, Li Pira G, Pende D, Falco M, Pagliara D, et al. Infusion of donor T cells transduced with inducible Caspase 9 (BPX-501 cells) is a safe and effective strategy to accelerate immune recovery in patients with non-malignant disorders after T cell depleted haplo-HSCT. Bone Marrow Transplant. 2016;51:S4–5. Preliminary data on a study protocol in children given haploidentical HSCT after depletion of TCRαβ + T lymphocytes and CD19+ B cells, coupled with the add-back of donor T-lymphocytes transduced with the suicide gene inducible Caspase 9.

    Google Scholar 

  32. • Locatelli F, Merli P, Strocchio L. Transplantation for thalassemia major: alternative donors. Curr Opin Hematol. 2016;23(6):515–23. Expert opinion review providing an overview of the state-of-the-art in alternative donor transplants in thalassemia.

  33. Sodani P, Isgro A, Gaziev J, Polchi P, Paciaroni K, Marziali M, et al. Purified T-depleted, CD34+ peripheral blood and bone marrow cell transplantation from haploidentical mother to child with thalassemia. Blood. 2010;115(6):1296–302.

    Article  CAS  PubMed  Google Scholar 

  34. Sodani P, Isgro A, Gaziev J, Paciaroni K, Marziali M, Simone MD, et al. T cell-depleted hla-haploidentical stem cell transplantation in thalassemia young patients. Pediatr Rep. 2011;3 Suppl 2:e13.

    PubMed  Google Scholar 

  35. Dallas MH, Triplett B, Shook DR, Hartford C, Srinivasan A, Laver J, et al. Long-term outcome and evaluation of organ function in pediatric patients undergoing haploidentical and matched related hematopoietic cell transplantation for sickle cell disease. Biol Blood Marrow Transplant. 2013;19(5):820–30.

    Article  PubMed  PubMed Central  Google Scholar 

  36. Bertaina A, Lucarelli B, Pagliara D, Merli P, Palumbo G, Pende D, et al. HLA haploidentical hematopietic stem cell transplantation after removal of alpha beta plus T lymphocytes for children with non-malignant disorders: a fulfilled promise. Bone Marrow Transplant. 2015;50:S39–40.

    Google Scholar 

  37. Bertaina A, Lucarelli B, Merli P, Bertaina V, Ferruzzi V, Pagliara D, et al. Clinical outcome after adoptive infusion of BPX-501 cells (donor T cells transduced with iC9 suicide gene) in children with thalassemia major (TM) given alfa/beta t-cell depleted hla-haploidentical stem cell transplantation (HSCT). Biol Blood Marrow Transplant. 2016;22(3):S306–S.

    Article  Google Scholar 

  38. O’Donnell PV, Luznik L, Jones RJ, Vogelsang GB, Leffell MS, Phelps M, et al. Nonmyeloablative bone marrow transplantation from partially HLA-mismatched related donors using posttransplantation cyclophosphamide. Biol Blood Marrow Transplant. 2002;8(7):377–86.

    Article  PubMed  Google Scholar 

  39. Luznik L, Jalla S, Engstrom LW, Iannone R, Fuchs EJ. Durable engraftment of major histocompatibility complex-incompatible cells after nonmyeloablative conditioning with fludarabine, low-dose total body irradiation, and posttransplantation cyclophosphamide. Blood. 2001;98(12):3456–64.

    Article  CAS  PubMed  Google Scholar 

  40. Kanakry CG, Ganguly S, Zahurak M, Bolanos-Meade J, Thoburn C, Perkins B, et al. Aldehyde dehydrogenase expression drives human regulatory T cell resistance to posttransplantation cyclophosphamide. Sci Transl Med. 2013;5(211):211ra157.

    Article  PubMed  PubMed Central  Google Scholar 

  41. Brodsky RA, Luznik L, Bolanos-Meade J, Leffell MS, Jones RJ, Fuchs EJ. Reduced intensity HLA-haploidentical BMT with post transplantation cyclophosphamide in nonmalignant hematologic diseases. Bone Marrow Transplant. 2008;42(8):523–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Bolanos-Meade J, Fuchs EJ, Luznik L, Lanzkron SM, Gamper CJ, Jones RJ, et al. HLA-haploidentical bone marrow transplantation with posttransplant cyclophosphamide expands the donor pool for patients with sickle cell disease. Blood. 2012;120(22):4285–91.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. de la Fuente J, O’Boyle F, Harrington Y, Bradshaw A, Hind S, Chakravorty S, et al. Haploidentical BMT with a post-infusion of stem cells cyclophosphamide approach is feasible and leads to a high rate of donor engraftment in haemoglobinopathies allowing universal application of transplantation. Blood. 2015;126(23):2.

    Google Scholar 

  44. • Anurathapan U, Hongeng S, Pakakasama S, Sirachainan N, Songdej D, Chuansumrit A, et al. Hematopoietic stem cell transplantation for homozygous beta-thalassemia and beta-thalassemia/hemoglobin E patients from haploidentical donors. Bone Marrow Transplant. 2016;51(6):813–8. Results from a T-cell replete haploidentical transplantation platform with post- transplant GvHD prophylaxis based on the use of cyclophosphamide and sirolimus or tacrolimus and mycophenolate mofetil.

  45. Clay J, Kulasekararaj AG, Potter V, Grimaldi F, McLornan D, Raj K, et al. Nonmyeloablative peripheral blood haploidentical stem cell transplantation for refractory severe aplastic anemia. Biol Blood Marrow Transplant. 2014;20(11):1711–6.

    Article  PubMed  Google Scholar 

  46. •• Esteves I, Bonfim C, Pasquini R, Funke V, Pereira NF, Rocha V, et al. Haploidentical BMT and post-transplant Cy for severe aplastic anemia: a multicenter retrospective study. Bone Marrow Transplant. 2015;50(5):685–9. In this small series, the use of a reduced-intensity conditioning with post-transplant Cy in haploidentical BMT was associated with high rates of engraftment and low risk of GVHD in patients with relapsed/refractory SAA.

  47. Thakar MS, Bonfim C, Sandmaier BM, O’Donnell P, Ribeiro L, Gooley T, et al. Cyclophosphamide-based in vivo T-cell depletion for HLA-haploidentical transplantation in Fanconi anemia. Pediatr Hematol Oncol. 2012;29(6):568–78.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Ayala E, LaFave D, Nishihori T, Kharfan-Dabaja MA. Haploidentical transplantation as a promising therapy for relapsed hemophagocytic lymphohistiocytosis in an older adult patient. Hematol Oncol Stem Cell Ther. 2016. doi:10.1016/j.hemonc.2016.05.005.

  49. Parta M, Hilligoss D, Kelly C, Kwatemaa N, Theobald N, Malech H, et al. Haploidentical hematopoietic cell transplantation with post-transplant cyclophosphamide in a patient with chronic granulomatous disease and active infection: a first report. J Clin Immunol. 2015;35(7):675–80.

    Article  CAS  PubMed  Google Scholar 

  50. Bahr TL, Lund T, Sando NM, Orchard PJ, Miller WP. Haploidentical transplantation with post-transplant cyclophosphamide following reduced-intensity conditioning for osteopetrosis: outcomes in three children. Bone Marrow Transplant. 2016;51(11):1546–8.

    Article  CAS  PubMed  Google Scholar 

  51. Jaiswal SR, Chakrabarti A, Chatterjee S, Ray K, Chakrabarti S. Haploidentical transplantation in children with unmanipulated peripheral blood stem cell graft: The need to look beyond post-transplantation cyclophosphamide in younger children. Pediatr Transplant. 2016;20(5):675–82.

    Article  CAS  PubMed  Google Scholar 

  52. Huang XJ, Liu DH, Liu KY, Xu LP, Chen H, Han W, et al. Haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion for the treatment of hematological malignancies. Bone Marrow Transplant. 2006;38(4):291–7.

    Article  PubMed  Google Scholar 

  53. Xu LP, Liu KY, Liu DH, Han W, Chen H, Chen YH, et al. A novel protocol for haploidentical hematopoietic SCT without in vitro T-cell depletion in the treatment of severe acquired aplastic anemia. Bone Marrow Transplant. 2012;47(12):1507–12.

    Article  CAS  PubMed  Google Scholar 

  54. Gao L, Li Y, Zhang Y, Chen X, Gao L, Zhang C, et al. Long-term outcome of HLA-haploidentical hematopoietic SCT without in vitro T-cell depletion for adult severe aplastic anemia after modified conditioning and supportive therapy. Bone Marrow Transplant. 2014;49(4):519–24.

    Article  CAS  PubMed  Google Scholar 

  55. Wang Z, Zheng X, Yan H, Li D, Wang H. Good outcome of haploidentical hematopoietic SCT as a salvage therapy in children and adolescents with acquired severe aplastic anemia. Bone Marrow Transplant. 2014;49(12):1481–5.

    Article  CAS  PubMed  Google Scholar 

  56. Xu LP, Wang SQ, Wu DP, Wang JM, Gao SJ, Jiang M, et al. Haplo-identical transplantation for acquired severe aplastic anaemia in a multicentre prospective study. Br J Haematol. 2016;175(2):265–74.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pediatric Hematology-Oncology, IRCCS, Bambino Gesù Children’s Hospital, Piazza Sant’Onofrio, 4 - 00165, Rome, Italy

    Alice Bertaina, Angela Pitisci, Matilde Sinibaldi & Mattia Algeri

Authors
  1. Alice Bertaina
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Angela Pitisci
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Matilde Sinibaldi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Mattia Algeri
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Alice Bertaina.

Ethics declarations

Conflict of Interest

The authors declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Stem Cell Transplantation

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bertaina, A., Pitisci, A., Sinibaldi, M. et al. T Cell-Depleted and T Cell-Replete HLA-Haploidentical Stem Cell Transplantation for Non-malignant Disorders. Curr Hematol Malig Rep 12, 68–78 (2017). https://doi.org/10.1007/s11899-017-0364-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11899-017-0364-3

Keywords

Search

Navigation